LONDON, Sept 30 (Reuters) - Animalcare Group Plc reported Tuesday full-year profits and sales
up as it integrates itself into Ritchey, and said the year was transformational for the company as it extends its focus from from farm-animal drugs to drugs for the fast-growing pet market.
The company, formed from the divested veterinary pharmaceuticals subsidiary of Genus Plc and agricultural supplier Ritchey Plc, booked pretax profit in line with the company's expectations, up 269 percent to 1.11 million pounds ($2 million) for the year ended June 30.
The company is recommending a higher-than-forecast dividend for the period of 2.25 pence per share, which it says reflects its confidence in the business.
It said the Ritchey livestock unit experienced lower sales due to the outbreaks of Foot & Mouth disease and Bluetongue, but this was mitigated by higher selling prices and robust cost control.
This follows a profit warning for the division issued in July.
(Reporting by Ben Deighton; Editing by Quentin Bryar)
COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.